Halozyme and Vertex signal deal for Hypercon expertise
Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a worldwide unique partnership and licensing settlement with Vertex Prescription drugs for the previous’s Hypercon expertise.
As a part of the settlement, Vertex has licensed the expertise to be used in as much as three drug targets.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
The Hypercon microparticle platform permits hyperconcentration of medicine and biologics, with the goal of decreasing injection quantity and facilitating at-home administration for sufferers.
Vertex will make an upfront fee of $15 million to Halozyme, together with potential future milestone funds. Halozyme may even obtain royalties on internet gross sales of all merchandise developed utilizing the expertise.
Halozyme Therapeutics president and CEO Helen Torley mentioned: “This collaboration with Vertex underlines the flexibility and potential of our Hypercon expertise to allow next-generation, low-volume patient-delivered biologics.
“Vertex is a confirmed innovator with deep experience, and we consider Hypercon can play an vital position in supporting better affected person entry to focused biologics which have the potential to advance innovation for sufferers with critical illnesses.”
Halozyme’s Enhanze drug supply expertise, based mostly on the enzyme rHuPH20, helps the subcutaneous supply of injected medicines and fluids to cut back therapy burden and enhance comfort.
Enhanze has been concerned in a couple of million affected person lives by way of ten commercialized merchandise in additional than 100 nations, and is licensed by corporations reminiscent of AbbVie, Eli Lilly, Pfizer, Roche, Takeda and ViiV Healthcare.
Halozyme has expanded its drug supply portfolio with Hypercon and Surf Bio’s polymer-based hyperconcentration expertise, increasing its capabilities for subcutaneous supply of biologics.
In January 2026, Takeda introduced a worldwide collaboration and licensing settlement with Halozyme to additional develop vedolizumab with the latter’s Enhanze drug supply expertise.
